Anti-GT253/ CERCAM/ CEECAM1 monoclonal antibody

Anti-GT253/ CERCAM/ CEECAM1 antibody for FACS & in-vivo assay

Target products collectionGo to CERCAM/CERCAM products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0254-Ab-1/ GM-Tg-hg-MP0254-Ab-2Anti-Human CERCAM monoclonal antibodyHuman
GM-Tg-rg-MP0254-Ab-1/ GM-Tg-rg-MP0254-Ab-2Anti-Rat CERCAM monoclonal antibodyRat
GM-Tg-mg-MP0254-Ab-1/ GM-Tg-mg-MP0254-Ab-2Anti-Mouse CERCAM monoclonal antibodyMouse
GM-Tg-cynog-MP0254-Ab-1/ GM-Tg-cynog-MP0254-Ab-2Anti-Cynomolgus/ Rhesus macaque CERCAM monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0254-Ab-1/ GM-Tg-felg-MP0254-Ab-2Anti-Feline CERCAM monoclonal antibodyFeline
GM-Tg-cang-MP0254-Ab-1/ GM-Tg-cang-MP0254-Ab-2Anti-Canine CERCAM monoclonal antibodyCanine
GM-Tg-bovg-MP0254-Ab-1/ GM-Tg-bovg-MP0254-Ab-2Anti-Bovine CERCAM monoclonal antibodyBovine
GM-Tg-equg-MP0254-Ab-1/ GM-Tg-equg-MP0254-Ab-2Anti-Equine CERCAM monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0254-Ab-1/ GM-Tg-hg-MP0254-Ab-2; GM-Tg-rg-MP0254-Ab-1/ GM-Tg-rg-MP0254-Ab-2;
GM-Tg-mg-MP0254-Ab-1/ GM-Tg-mg-MP0254-Ab-2; GM-Tg-cynog-MP0254-Ab-1/ GM-Tg-cynog-MP0254-Ab-2;
GM-Tg-felg-MP0254-Ab-1/ GM-Tg-felg-MP0254-Ab-2; GM-Tg-cang-MP0254-Ab-1/ GM-Tg-cang-MP0254-Ab-2;
GM-Tg-bovg-MP0254-Ab-1/ GM-Tg-bovg-MP0254-Ab-2; GM-Tg-equg-MP0254-Ab-1/ GM-Tg-equg-MP0254-Ab-2
Products NameAnti-CERCAM monoclonal antibody
Formatmab
Target NameCERCAM
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CERCAM benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species GT253/ CERCAM/ CEECAM1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0254
    Target NameCERCAM
    Gene ID51148,99151,296616,114669811,609012,101093309,516122,100070231
    Gene Symbol and Synonyms2600006K01Rik,CEECAM1,CERCAM,GLT25D3
    Uniprot AccessionQ5T4B2,Q5U309,A7MB73
    Uniprot Entry NameGT253_HUMAN,GT253_RAT,GT253_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000167123
    Target ClassificationN/A

    The target: CERCAM, gene name: CERCAM, also named as CEECAM1, GLT25D3. Enables identical protein binding activity. Acts upstream of or within cell adhesion. Predicted to be located in endoplasmic reticulum lumen. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.